Table 3.
Summary of the main pooled effect estimates (95 % CI) of studies comparing mHealth to control with data on both the treatment and the control arms stratified by 1) questionnaire type and when feasible 2) intervention type.
| Questionnaire type | Pooled effect estimate for HRQoL | Studies reporting data on both arms; # of studies | I2 %; P-heterogeneity |
|---|---|---|---|
| EORTC QLQ-C30 Global Health Status (Overall)* | Mean difference (95 % CI) | 3.66 (-0.94, 8.26); n = 3 | 81.5%; p < 0.01 |
| SF-36 (Overall)* | Mean difference (95 % CI) | 15.4 (5.30, 25.5); n = 3 | 0%; p: 0.49 |
| FACT-G (Overall) | Mean difference (95 % CI) | 5.86 (0.77, 11.0); n = 1 | NA |
| All combined (Overall) | SMD (95 % CI) | 0.28 (0.03, 0.53); n=6 | 61.4 %; p: 0.02 |
| EORTC QLQ-C30 Global Health Status | 0.27 (-0.06, 0.59); n = 3 | 80.7 %; p < 0.01 | |
| SF-36 | 0.17 (-0.32, 0.66); n = 2 | 0%; p: 0.50 | |
| FACT-G | 0.54 (-0.14, 1.21); n = 1 | NA | |
| p-interaction | p-int:0.68 |
CI: confidence interval; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; FACT-G: Functional Assessment of Cancer Therapy-General; HRQol: Health-related quality of life; NA: not applicable; SF-36: Medical Outcomes Study 36-Item Short Form; SMD: standardized mean difference.